CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Zinc +1 moredietary
Likely dose
Zinc 25 mg of elemental zinc as zinc sulphate once daily for 18 monthsAI-extracted
Key inclusion· 3
  • ✓Age 6 to 30 years
  • ✓Diagnosis of thalassemia
  • ✓Bone mineral density Z-score less than −1.0 on DXA scan
Key exclusion· 7
  • ✕History of bone marrow transplant
  • ✕Current treatment for low bone mass (other than calcium or vitamin D), such as calcitonin or bisphosphonates
  • ✕Currently taking zinc supplementation and unable or unwilling to stop during trial
  • ✕Participating in another trial with a medication affecting bone mineral density

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00459732
NCT00459732N/ACompleted
CompareCT.gov

Zinc and Bone Metabolism in Thalassemia

UCSF Benioff Children's Hospital Oakland·interventional·Posted Apr 12, 2007·Updated Dec 4, 2020

In Brief

A clinical study evaluating Zinc and Placebo for Thalassemia. Completed, enrolled 45 participants across 3 sites.

Detailed Summary

The purpose of this study is to test whether zinc can improve bone health in young patients with thalassemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThalassemia
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Children's Hospital of Philadelphia, University of California, San Francisco

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 12, 2007
Enrollment StartApr 1, 2006
Primary CompletionOct 1, 2009
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 19.2 years ago

Interventions

Zincdietary

25 mg of elemental zinc as zinc sulphate take once daily for 18 months

Placebodietary

Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months